# Primary Prophylaxis for Spontaneous Bacterial Peritonitis

> **NCT04775329** · PHASE2,PHASE3 · TERMINATED · sponsor: **Changi General Hospital** · enrollment: 2 (actual)

## Conditions studied

- Decompensated Cirrhosis
- Small Bowel Bacterial Overgrowth Syndrome

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT04775329
- **Lead sponsor:** Changi General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow recruitment and study closure
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775329, "Primary Prophylaxis for Spontaneous Bacterial Peritonitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04775329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*